Bradley Foster & Sargent Inc. CT Has $14.98 Million Stock Position in Pfizer Inc. $PFE

Bradley Foster & Sargent Inc. CT raised its position in Pfizer Inc. (NYSE:PFE) by 12.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 587,805 shares of the biopharmaceutical company’s stock after purchasing an additional 65,206 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Pfizer were worth $14,977,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Vanguard Group Inc. raised its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares in the last quarter. Geode Capital Management LLC grew its position in Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after acquiring an additional 1,820,634 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer during the 2nd quarter valued at $2,270,157,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Pfizer by 2.0% in the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after purchasing an additional 950,239 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $27.14 on Wednesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market cap of $154.29 billion, a P/E ratio of 19.95 and a beta of 0.47. The business’s 50 day moving average is $25.99 and its two-hundred day moving average is $25.36. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the company posted $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. Pfizer’s payout ratio is presently 126.47%.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. HSBC reaffirmed a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Scotiabank initiated coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $27.70.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: U.S. FDA gave full approval to BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil‑based chemotherapy for first‑line BRAF V600E metastatic colorectal cancer — this converts prior trial success into an approved market opportunity with clearer commercialization and revenue potential. U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
• Positive Sentiment: Pfizer struck a China commercialization/licensing deal for Sciwind’s ecnoglutide (a biased GLP‑1) for type 2 diabetes/weight management with up to ~$495M in potential payments — expands Pfizer’s metabolic/obesity footprint in a large growth market. Pfizer in diabetes drug deal with Sciwind Biosciences
• Positive Sentiment: Pipeline momentum: coverage highlights Pfizer’s obesity push (acquisitions and >20 weight‑management studies) alongside positive BREAKWATER oncology readouts — reinforces diversified growth drivers beyond legacy products. Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
• Positive Sentiment: Dividend support: coverage notes Pfizer’s commitment to its dividend, yielding ~6.4%, which can attract and retain income‑oriented investors and provide downside support for the stock. This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
• Neutral Sentiment: Management visibility: Pfizer will webcast CEO Albert Bourla’s discussion at the TD Cowen conference on March 2 — could provide forward guidance or pipeline commentary that moves the stock depending on tone. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Neutral Sentiment: Operational/innovation note: Telescope Innovations installed a second self‑driving lab at Pfizer — indicates investment in R&D efficiency but limited immediate revenue impact. Telescope Innovations Installs Second Self-Driving Lab at Pfizer

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.